Robot | Path | Permission |
GoogleBot | / | ✔ |
BingBot | / | ✔ |
BaiduSpider | / | ✔ |
YandexBot | / | ✔ |
Title | COVID-19 and N2-01 - N2 |
Description | TECHNOLOGY COVID-19 OTHER APPLICATIONS TEAM TECHNOLOGY COVID-19 Close × TECHNOLOGY COVID-19 OTHER APPLICATIONS TEAM COVID-19 treatment candidate Severity, |
Keywords | N/A |
WebSite | n2pharma.co.uk |
Host IP | 195.24.68.9 |
Location | Russian Federation |
Site | Rank |
US$1,365
Last updated: 2022-07-17 10:44:12
n2pharma.co.uk has Semrush global rank of 0. n2pharma.co.uk has an estimated worth of US$ 1,365, based on its estimated Ads revenue. n2pharma.co.uk receives approximately 157 unique visitors each day. Its web server is located in Russian Federation, with IP address 195.24.68.9. According to SiteAdvisor, n2pharma.co.uk is safe to visit. |
Purchase/Sale Value | US$1,365 |
Daily Ads Revenue | US$1 |
Monthly Ads Revenue | US$37 |
Yearly Ads Revenue | US$453 |
Daily Unique Visitors | 10 |
Note: All traffic and earnings values are estimates. |
Host | Type | TTL | Data |
n2pharma.co.uk. | A | 3598 | IP: 195.24.68.9 |
n2pharma.co.uk. | NS | 3600 | NS Record: ns8.nic.ru. |
n2pharma.co.uk. | NS | 3600 | NS Record: ns4.nic.ru. |
n2pharma.co.uk. | NS | 3600 | NS Record: ns3.nic.ru. |
n2pharma.co.uk. | MX | 3600 | MX Record: 20 mx03.nicmail.ru. |
n2pharma.co.uk. | MX | 3600 | MX Record: 5 mx02.nicmail.ru. |
n2pharma.co.uk. | MX | 3600 | MX Record: 10 mx01.nicmail.ru. |
n2pharma.co.uk. | TXT | 3600 | TXT Record: v=spf1 redirect=nicmail.ru |
TECHNOLOGY COVID-19 OTHER APPLICATIONS TEAM TECHNOLOGY COVID-19 Close × TECHNOLOGY COVID-19 OTHER APPLICATIONS TEAM COVID-19 treatment candidate Severity, morbidity and mortality of COVID-19 are linked to endothelial dysfunction N2-01 has proven to reduce the level of endothelial dysfunction both in laboratory settings and clinical usage MHRA confirmed the plausibility of these scientific arguments and reduced the requirements for initial testing N2-01 is already proven to be safe and effective in veterinary applications related to endothelial dysfunction Available not-for-profit to patients with COVID-19, if proven effective More about the role of the endothelium COVID-19 treatment candidate Severity, morbidity and mortality of COVID-19 are linked to endothelial dysfunction N2-01 has proven to reduce the level of endothelial dysfunction both in laboratory settings and clinical usage MHRA confirmed the plausibility of these scientific arguments and reduced the requirements for initial |
HTTP/1.1 301 Moved Permanently Server: openresty/1.19.9.1 Date: Tue, 02 Nov 2021 16:16:35 GMT Content-Type: text/html; charset=iso-8859-1 Connection: keep-alive Location: https://n2pharma.co.uk/ HTTP/2 200 server: openresty/1.19.9.1 date: Tue, 02 Nov 2021 16:16:36 GMT content-type: text/html; charset=UTF-8 content-length: 55707 accept-ranges: bytes |